fasudil has been researched along with Sclerosis, Systemic in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study aimed firstly to describe pulmonary inflammation and fibrosis induced by HOCl in mice, and secondly to determine whether fasudil, a selective inhibitor of ROCK, could prevent lung and skin fibroses in HOCl-injected mice." | 1.43 | RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. ( Batteux, F; Bei, Y; Chéreau, C; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Le-Dong, NN; Nicco, C; Tiev, KP, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pernis, AB | 1 |
| Ricker, E | 1 |
| Weng, CH | 1 |
| Rozo, C | 1 |
| Yi, W | 1 |
| Bei, Y | 1 |
| Hua-Huy, T | 1 |
| Nicco, C | 1 |
| Duong-Quy, S | 1 |
| Le-Dong, NN | 1 |
| Tiev, KP | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| Dinh-Xuan, AT | 1 |
| Fava, A | 1 |
| Wung, PK | 1 |
| Wigley, FM | 1 |
| Hummers, LK | 1 |
| Daya, NR | 1 |
| Ghazarian, SR | 1 |
| Boin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon[NCT03984422] | 120 participants (Anticipated) | Observational | 2020-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fasudil and Sclerosis, Systemic
| Article | Year |
|---|---|
Rho Kinases in Autoimmune Diseases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Arthritis, Rheumatoid; Autoimmune Di | 2016 |
1 trial available for fasudil and Sclerosis, Systemic
| Article | Year |
|---|---|
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
1 other study available for fasudil and Sclerosis, Systemic
| Article | Year |
|---|---|
RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Disease Models, Animal; Female; Hypo | 2016 |